Research Topics
| B E SandsSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's diseaseB E Sands
Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 117:58-64. 1999..kg-1. wk-1 given 2 or 5 times weekly for 3 weeks. Clinical and laboratory safety data were recorded, and disease activity was measured at each visit...- From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammationBruce E Sands
Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, Massachusetts 02114 USA
Gastroenterology 126:1518-32. 2004 - The role of TNFalpha in ulcerative colitisBruce E Sands
Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Diseases, and MGH Crohn s and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
J Clin Pharmacol 47:930-41. 2007..Soluble TNFalpha receptors or biologic agents that suppress or inhibit TNFalpha production may also show therapeutic promise... - Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximabBruce E Sands
Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Inflamm Bowel Dis 13:2-11. 2007..Natalizumab, a humanized monoclonal IgG(4) antibody to alpha4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied... - Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II StudyBruce E Sands
Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Gastroenterol Hepatol 2:912-20. 2004..This post hoc analysis was conducted to determine the efficacy and safety of infliximab therapy in women with rectovaginal fistulas... - Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practiceBruce E Sands
Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA, USA
J Clin Gastroenterol 40:587-91. 2006..The aims of this study are to assess consistency between: (1) community physicians and established treatment guidelines in their respective operational definitions of severity and (2) clinical severity ratings and resulting treatment... - A survey of methodological variation in the Crohn's disease activity indexBruce E Sands
Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Inflamm Bowel Dis 11:133-8. 2005..The Crohn's disease activity index (CDAI) is the most widely used Crohn's disease activity instrument, yet little is known about the methodological variation in its use... - New therapies for the treatment of inflammatory bowel diseaseBruce E Sands
MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
Surg Clin North Am 86:1045-64. 2006..As we continue to learn about how best to use the agents currently in our hands, the addition of new drugs will further improve outcomes, and will bring new insights into the fundamental causes of these diseases... - Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validationBruce E Sands
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Pharmacoepidemiol Drug Saf 15:47-56. 2006..This report describes the development and validation of claims-based algorithms to identify colonic ischemia, hospitalized complications of constipation, and irritable bowel syndrome (IBS)... - Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn diseaseBruce E Sands
Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Gastroenterol 40:482-9. 2006.... - Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II studyB E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Aliment Pharmacol Ther 23:1127-36. 2006..Rapid fistula healing may predispose Crohn's disease patients to abscess development... 
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitisBruce E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 135:400-9. 2008..Open-label studies and clinical experience in Japan and Europe have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative colitis...
Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?B E Sands
MGH Crohn s and Colitis Center, Massachusetts General and Gastrointestinal Unit Hospital, 165 Cambridge St, 9th Floor, Boston, MA 02114, USA
Gut 55:437-41. 2006..Although the evidence base in support of immunosuppressive drugs in ulcerative colitis is not as strong as in Crohn's disease, these agents clearly have a role in the treatment of this disease...- Fulminant colitisBruce E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, 9th Floor, Boston, MA 02114, USA
J Gastrointest Surg 12:2157-9. 2008..A great deal of judgment is needed to guide the timing of colectomy, but it is clear that mortality increases as the time to colectomy is prolonged... - Therapy of inflammatory bowel diseaseB E Sands
Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
Gastroenterology 118:S68-82. 2000..This review covers agents currently used in the treatment of IBD and seeks to provide an overview of emerging therapies... - Medical therapy of steroid-resistant Crohn's diseaseB E Sands
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Can J Gastroenterol 14:33C-37C. 2000..Limited data are available on the use of tacrolimus, mycophenolate mofetil and thalidomide. Steroid-resistant Crohn's disease, while involving a small minority of patients, continues to present a difficult therapeutic challenge... - Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseBruce E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Inflamm Bowel Dis 16:1209-18. 2010..We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD... - The placebo response rate in irritable bowel syndrome and inflammatory bowel diseaseBruce E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Dig Dis 27:68-75. 2009..In the future, improved understanding of the factors that drive the placebo response rate should lead to more efficient study design and drug development... - Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's diseaseB E Sands
Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, 02114, USA
Aliment Pharmacol Ther 16:399-406. 2002..Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease... - Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyB E Sands
Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston 02114, USA
Inflamm Bowel Dis 7:83-8. 2001..Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis... - Review article: Medical therapy for fistulizing Crohn's diseaseB Bressler
Gastrointestinal Unit and MGH Crohn's and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Aliment Pharmacol Ther 24:1283-93. 2006..001). CONCLUSION: Further research to find new therapies and to improve our existing medical treatment of fistulizing Crohn's disease is required... - Infliximab maintenance therapy for fistulizing Crohn's diseaseBruce E Sands
Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
N Engl J Med 350:876-85. 2004.... - Biologicals: principles, techniques and mechanisms of actionB E Sands
Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, Boston, USA
Acta Gastroenterol Belg 64:165-9. 2001..This paper is intended to highlight the methodological principles behind biologic agents, methods of discovery and production, and to highlight potential therapeutic targets for these new agents... - Biological therapies for ulcerative colitisB E Sands
Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, Boston, USA
Acta Gastroenterol Belg 64:205-9. 2001..The role of probiotic therapy, and studies of cytokine-directed therapies, therapies targeting adhesion and recruitment, and restitution and repair are described... - Effects of growth hormone secretion on body composition in patients with Crohn's diseaseLaurence Katznelson
Neuroendocrine Unit and General Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
J Clin Endocrinol Metab 88:5468-72. 2003..These data show that GH has an important role in modulating visceral fat distribution in patients with Crohn's disease... - Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel diseaseA Tinsley
Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, NY 10029, USA
Aliment Pharmacol Ther 34:1328-36. 2011..76, 95% CI -0.89 to -0.50), CRP (-0.72, 95% CI -0.88 to -0.43) and HCT (0.53, 95% CI 0.22-0.74). CONCLUSION The FACIT-F scale is a reliable and valid instrument for measuring fatigue in IBD... - Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasmsC G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 46:995-8. 2000..To clarify the use of this modality in this setting, this study assesses the short- and long-term tolerance of 28 patients with IBD to abdominal and pelvic irradiation... - Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complicationsHiroko Kunitake
Department of Surgery, Massachusetts General Hospital, 15 Parkman Street, ACC 460, Boston, MA 02114, USA
J Gastrointest Surg 12:1730-6; discussion 1736-7. 2008..We examined a large patient cohort to clarify whether a relationship exists between IFX and postoperative complications... - Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysisG G Kaplan
Massachusetts General Hospital, Gastrointestinal Unit, Boston, MA, USA
Aliment Pharmacol Ther 26:1509-20. 2007..Crohn's disease patients who have lost response to 5 mg/kg of infliximab may regain response by increasing the dose of infliximab to 10 mg/kg. Alternatively, adalimumab can be used as a rescue therapy... - Inflammatory bowel disease: past, present, and futureBruce E Sands
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
J Gastroenterol 42:16-25. 2007..Future directions in the IBD will likely explicate the inhomogeneous causes of these diseases, with implications for individualized therapy... - Risk factors for colorectal cancer in Crohn's colitis: a case-control studyCorey A Siegel
Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Medical School, Lebanon, NH, and Gastrointestinal Unit, MGH Crohn's and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
Inflamm Bowel Dis 12:491-6. 2006..These data underscore the importance of CRC surveillance for Crohn's colitis in addition to ulcerative colitis and should prompt further study in this area... - Guidelines for immunizations in patients with inflammatory bowel diseaseBruce E Sands
Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Inflamm Bowel Dis 10:677-92. 2004..We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population... - Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease QuestionnaireManuel Y Lam
MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Inflamm Bowel Dis 15:599-607. 2009..We assessed the validity of an interactive voice response system (IVRS) as a new mode of administering the SIBDQ... - Why do anti-tumor necrosis factor antibodies work in Crohn's disease?Bruce E Sands
Gastrointestinal Unit and MGH Inflammatory Bowel Disease Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Rev Gastroenterol Disord 4:S10-7. 2004..Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations... - Review article: practical management of inflammatory bowel disease patients taking immunomodulatorsC A Siegel
Gastrointestinal Unit and MGH Crohn's and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Aliment Pharmacol Ther 22:1-16. 2005..Immunomodulators are important agents for the treatment of Crohn's disease and ulcerative colitis, and prescribing clinicians should be comfortable recognizing both their value and their limitations... - Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's diseaseAlexandra Gutierrez
Gastrointestinal Unit and MGH Crohn's and Colitis Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Am J Gastroenterol 101:2283-9. 2006..One-third of patients treated with percutaneous drainage required surgery within 1 yr. Earlier intervention for abdominal and pelvic abscesses is associated with shorter time to resolution... - Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysisCorey A Siegel
Dartmouth Hitchcock IBD Center and Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Massachusetts, USA
Clin Gastroenterol Hepatol 7:874-81. 2009.... - Design issues and outcomes in IBD clinical trialsBruce E Sands
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Inflamm Bowel Dis 11:S22-8. 2005..Careful subject selection, standardization of disease activity indices, and precise outcome measurement are the keys to continued improvement of the inflammatory bowel disease research process... - Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's diseaseD G Forcione
Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Gut 53:1117-22. 2004..CONCLUSIONS: Patients with Crohn's disease who are positive for ASCA IgA, IgG, or both, may define a subset of patients with Crohn's disease at increased risk for early surgery... - The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and DenmarkGilaad G Kaplan
MGH Crohn s and Colitis Center, Boston, Massachusetts, USA
Gut 56:1387-92. 2007..The relationship between appendectomy and Crohn's disease is controversial. A Swedish-Danish cohort study was conducted to assess the risk of developing Crohn's disease after an appendectomy... - Risk of early surgery for Crohn's disease: implications for early treatment strategiesBruce E Sands
Gastrointestinal Unit and Center for the Study of IBD, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, MA 02114, USA
Am J Gastroenterol 98:2712-8. 2003..These results suggest that improved risk stratification and potent therapies with rapid onset of action are needed to modify the natural history of Crohn's disease... - Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter speciesMitchell J Schwaber
Department of Medicine, Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, Massachusetts, USA
Antimicrob Agents Chemother 47:1882-6. 2003..and the equivalence in risk associated with piperacillin-tazobactam and broad-spectrum cephalosporins may have important clinical and epidemiologic implications... - LRRK2 is involved in the IFN-gamma response and host response to pathogensAgnès Gardet
Center for the Study of the Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Immunol 185:5577-85. 2010..These observations indicate that LRRK2 is an IFN-γ target gene, and it might be involved in signaling pathways relevant to Crohn's disease pathogenesis... - Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochlorideDavid P Miller
Ingenix, Epidemiology Division, Newton, Massachusetts 02466, USA
Am J Gastroenterol 98:1117-22. 2003..On June 7, 2002, the Food and Drug Administration approved alosetron for reintroduction in the U.S. market for women with severe diarrhea-related IBS... - State of the art: IBD therapy and clinical trials in IBDKim L Isaacs
University of North Carolina, Chapel Hill, North Carolina, USA
Inflamm Bowel Dis 11:S3-12. 2005..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD... - Occurrence of colon ischemia in relation to irritable bowel syndromeJ Alexander Cole
Ingenix Epidemiology, Newton, Massachusetts 02466, USA
Am J Gastroenterol 99:486-91. 2004..Alternatively, it may be a consequence of therapy, or a manifestation of other bowel pathology that is sometimes confused with IBS... - Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Gastroenterology 134:688-95. 2008..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)... - Risks and benefits of infliximab for the treatment of Crohn's diseaseCorey A Siegel
Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
Clin Gastroenterol Hepatol 4:1017-24; quiz 976. 2006..These data should help guide decision making and the informed consent process when considering the use of infliximab for the treatment of Crohn's disease... - Selective leukocyte apheresis for the treatment of inflammatory bowel diseaseMaria T Abreu
Inflammatory Bowel Disease Center, New York, NY, USA
J Clin Gastroenterol 41:874-88. 2007..Despite these findings, large controlled trials of selective leukocyte apheresis in the treatment of IBD are needed to determine the true efficacy of this approach... - A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosisMilton D Rossman
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Sarcoidosis Vasc Diffuse Lung Dis 23:201-8. 2006..CONCLUSIONS: Infliximab may improve VC in patients with active PS resistant to steroids. Larger scale, longer term studies will be needed to assess both safety and efficacy... - Risk factors for colon ischemiaAlexander M Walker
Ingenix Epidemiology, Auburndale, Massachusetts 02466, USA
Am J Gastroenterol 99:1333-7. 2004..The frequency of preceding doctor visits, without a specific diagnosis, suggests that colon ischemia may have a prolonged subacute presentation... - Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's diseaseGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Gastroenterology 128:862-9. 2005..We examined the effect of infliximab maintenance treatment on hospitalizations, surgeries, and procedures in patients with fistulizing Crohn's disease enrolled in the ACCENT II study... - Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacyF Reed Johnson
Research Triangle Institute RTI International, Research Triangle Park, North Carolina, USA
Gastroenterology 133:769-79. 2007..The aim of this study is to estimate the willingness of Crohn's disease (CD) patients to accept life-threatening adverse event risks in exchange for CD symptom relief... - Infliximab for induction and maintenance therapy for ulcerative colitisPaul Rutgeerts
University Hospital Gasthuisberg, Leuven, Belgium
N Engl J Med 353:2462-76. 2005..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis... - Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitisGilaad G Kaplan
Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
Gastroenterology 134:680-7. 2008..We set out to evaluate postoperative morbidity and mortality using a nationally representative database and to determine the factors that influenced outcomes... - American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark
Department of Pathology, Cambridge University, Cambridge, England
Gastroenterology 133:312-39. 2007..Abbott Laboratories representatives did not attend the conference, nor did they participate in any way in the development of this report... - Acute appendicitis following colonoscopyMichael J Rosen
J Clin Gastroenterol 39:78. 2005 - Prevention and treatment of osteoporosis in inflammatory bowel diseaseGary R Lichtenstein
University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104 4283, USA
Inflamm Bowel Dis 12:797-813. 2006..They should not be interpreted as quality standards... - Possible association between isotretinoin and inflammatory bowel diseaseDeepa Reddy
Department of Medicine, University of Chicago, Chicago, Illinois, USA
Am J Gastroenterol 101:1569-73. 2006..quot; CONCLUSIONS: In a subgroup of patients, isotretinoin might serve as a trigger for IBD... - Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel diseaseCorey A Siegel
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
Inflamm Bowel Dis 14:1-6. 2008..The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (IBD)...
Research Grants
- IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASEBRUCE SANDS; Fiscal Year: 2004..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
- IMURAN Dose Ranging Study in Crohn's DiseaseBRUCE SANDS; Fiscal Year: 2005..Abstract Not Provided ..
- OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory BoBRUCE SANDS; Fiscal Year: 2007..We will follow these patients over time to determine the progression of their disease and to compare this to markers in the blood as a way of developing a system to predict the individual course of disease. ..